Saturday 17 October 2026
Export DYN’s income statement to Excel — free account
Dyne Therapeutics, Inc.
In the quarter to June 2026, EPS fell 11.3%, free cash flow fell 39.1% and total debt rose 116.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
14.25
1.04
−6.80%
Follow DYN
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 11.47 | 6.26 | 31.83 | 13.31 | 9.46 | 2.53 | 15.60 | 22.25 |
Net Debt/EBITDA |
— | 1.00 | 1.08 | 5.97 | 2.38 | 1.37 | 0.51 | 1.86 | 2.05 |
Debt/Assets |
0.00% | 40.82% | 0.00% | 0.00% | 6.75% | 8.45% | 0.00% | 0.00% | 12.55% |
Debt/Equity |
— | 0.81 | 0.00 | 0.00 | 0.08 | 0.10 | 0.00 | 0.00 | 0.15 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.87 | 0.80 | 0.78 | 0.80 | 0.91 | 0.80 | 0.92 | 0.90 |
Capex/Depreciation |
— | 0.00 | (6.08) | (1.50) | (0.99) | (1.04) | (1.28) | 1.23 | (8.97) |
Interest Coverage |
— | (1,918.00) | (47.68) | (148.10) | (202.19) | (58.61) | — | — | (75.61) |
| — | 52.66% | 162.64% | (36.13%) | (42.02%) | (54.18%) | (137.31%) | (88.03%) | (55.71%) | |
| — | (116.38%) | (120.30%) | (32.15%) | (38.33%) | (45.93%) | (100.10%) | (74.14%) | (47.52%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (460.33%) | (480.77%) | 0.00% | 0.00% | (2,790.00%) |
Return on Tangible Assets |
— | (63.66%) | (107.00%) | (17.48%) | (41.66%) | (69.05%) | (284.06%) | (51.00%) | (40.57%) |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.09) | (5.52) | (3.31) | (2.42) | (3.02) | (3.16) | (3.13) | (3.15) |
Cash per Share |
— | 0.18 | 5.99 | 23.99 | 7.40 | 4.93 | 2.06 | 6.82 | 8.65 |
Shareholders Equity per Share |
— | 0.09 | 5.75 | 23.78 | 7.23 | 4.86 | 1.53 | 6.69 | 7.57 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.09 | 5.75 | 23.78 | 7.23 | 4.86 | 1.53 | 6.69 | 7.57 |
Free Cash Flow |
— | (4.16) | (13.48) | (47.67) | (123.18) | (156.71) | (188.89) | (294.74) | (405.13) |
Working Capital |
— | 7.45 | 12.40 | 338.12 | 353.67 | 237.51 | 78.28 | 617.02 | 1,075.96 |
Capital Expenditures |
— | (0.13) | (1.65) | (1.16) | (3.62) | (3.07) | (0.73) | (2.38) | (1.92) |
Net Current Asset Value |
— | 4.07 | 12.36 | 338.12 | 324.93 | 211.63 | 55.59 | 597.88 | 911.76 |
| Other line items | |||||||||
Quick Ratio |
— | 11.43 | 6.21 | 31.49 | 13.11 | 9.11 | 2.41 | 15.20 | 21.94 |
Depreciation/Fixed assets |
— | 0.22 | 0.18 | 0.40 | 0.78 | 0.50 | 0.12 | (0.36) | 0.01 |
Cash ROIC |
— | (26.55%) | (47.02%) | (6.93%) | (15.92%) | (29.33%) | (88.10%) | (23.17%) | (18.15%) |
Accounts Payable Turnover |
— | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 7,877.92 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.09) | (4.84) | (3.23) | (2.35) | (2.96) | (3.15) | (3.11) | (3.14) |
Capex per Share |
— | 0.00 | (0.67) | (0.08) | (0.07) | (0.06) | (0.01) | (0.03) | (0.01) |
Average Payables |
— | 0.89 | 0.89 | 2.35 | 3.74 | 4.65 | 14.10 | 14.75 | 7.32 |
Average Assets |
— | 4.13 | 12.35 | 184.89 | 389.50 | 365.99 | 235.70 | 428.16 | 939.10 |
Average Common Equity |
— | (9.14) | (9.14) | 164.49 | 355.28 | 310.28 | 171.83 | 360.57 | 800.98 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates